SPY456.49-8.23 -1.77%
DIA353.85-5.29 -1.47%
IXIC14,506.90-386.86 -2.60%

BRIEF-Eagle Pharmaceuticals Receives 180 Days Of Marketing Exclusivity For Recently Approved Vasopressin

reuters.com · 12/29/2021 11:26
BRIEF-Eagle Pharmaceuticals Receives 180 Days Of Marketing Exclusivity For Recently Approved Vasopressin

- Eagle Pharmaceuticals Inc EGRX:

  • EAGLE PHARMACEUTICALS RECEIVES 180 DAYS OF MARKETING EXCLUSIVITY FOR RECENTLY APPROVED VASOPRESSIN

Source text for Eikon: nBw4d3tqca

Further company coverage: EGRX


((Reuters.Briefs@thomsonreuters.com;;))